Macitentan

• Description :

  Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) [1].

• Product Name Alternative :

  ACT-064992

• UNSPSC :

  12352005

• Hazard Statement :

  H360

• Target :

  Apoptosis; Endothelin Receptor

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease; Endocrinology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Macitentan.html

• Concentration :

  10mM

• Purity :

  99.87

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  BrC1=CN=C(OCCOC2=C(C3=CC=C(Br)C=C3)C(NS(NCCC)(=O)=O)=NC=N2)N=C1

• Molecular Formula :

  C19H20Br2N6O4S

• Molecular Weight :

  588.27

• Precautions :

  H360

• References & Citations :

  [1]Corallo C, et al. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther. 2016 Oct 6;18 (1) :228.|[2]Sen S, et al. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist. Life Sci. 2012 Apr 13.|[3]Bruderer S, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J. 2012 Mar;14 (1) :68-78.|[4]Kim SJ, et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol. 2012 Feb;5 (1) :39-47.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  ETA; ETB

• CAS Number :

  [441798-33-0]